Free tool
FAERS Monitor: Serevent
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020692 or its brand name (Serevent, Salmeterol Xinafoate). Reports on generic versions are filed under their own applications.
Reports
8,614
Serious
5,067
59% of reports
Hospitalization
2,500
Death reported
965
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,269
- drug ineffective1,232
- asthma919
- cough597
- headache474
- pneumonia413
- nausea403
- wheezing378
- dizziness368
- chest discomfort357
- fatigue355
- pharmaceutical product complaint318
- chest pain317
- malaise303
- diarrhoea289
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,507 |
| 2005 | 678 |
| 2006 | 562 |
| 2007 | 426 |
| 2008 | 446 |
| 2009 | 446 |
| 2010 | 433 |
| 2011 | 313 |
| 2012 | 283 |
| 2013 | 316 |
| 2014 | 328 |
| 2015 | 331 |
| 2016 | 370 |
| 2017 | 282 |
| 2018 | 292 |
| 2019 | 307 |
| 2020 | 252 |
| 2021 | 245 |
| 2022 | 178 |
| 2023 | 171 |
| 2024 | 231 |
| 2025 | 126 |
| 2026 | 88 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,545 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pharmaceutical product complaintSignal | 318 | 30.3 | 27.1 | 8,870 |
| asthmaSignal | 919 | 20.0 | 18.8 | 16,532 |
| wheezingSignal | 378 | 15.7 | 14.2 | 5,153 |
| chest discomfortSignal | 357 | 8.5 | 7.7 | 2,372 |
| dyspnoeaSignal | 1,269 | 5.5 | 5.2 | 4,765 |
| coughSignal | 597 | 5.2 | 4.8 | 2,048 |
| chest painSignal | 317 | 4.2 | 3.8 | 771 |
| pneumoniaSignal | 413 | 3.1 | 2.8 | 600 |
| drug ineffectiveSignal | 1,232 | 2.3 | 2.2 | 946 |
| headache | 474 | 1.8 | 1.7 | 189 |
| dizziness | 368 | 1.8 | 1.6 | 134 |
| malaise | 303 | 1.7 | 1.5 | 86 |
| nausea | 403 | 1.2 | 1.1 | 20 |
| fatigue | 355 | 1.1 | 1.0 | 4 |
| diarrhoea | 289 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.